Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 11, 2002, Pages 3472-3477

  Saraiva, Victor B ^a   Gibaldi, Daniel ^a   Previato, José O ^a   Mendonça Previato, Lucia ^a   Bozza, Marcelo T ^a   Freire de Lima, Célio G ^a   Heise, Norton ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; MILTEFOSINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHOLIPID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; AMASTIGOTE; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; EPIMASTIGOTE; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; SURVIVAL; TRYPANOSOMA CRUZI;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; DRUG RESISTANCE; EXUDATES AND TRANSUDATES; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROIMIDAZOLES; OMEGA-N-METHYLARGININE; PHOSPHORYLCHOLINE; SURVIVAL ANALYSIS; TRYPANOSOMA CRUZI; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036840473     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.11.3472-3477.2002     Document Type: Article

References (44)

1. Andrews, N. W., M. J. M. Alves, R. I. Schumacher, and W. Colli. 1985. Trypanosoma cruzi: protection in mice immunized with 8-methoxypsolaren-inactivated trypomastigotes. Exp. Parasitol. 60:255-262.
2. Arana, B., N. Rizzo, and A. Diaz. 2001. Chemotherapy of cutaneous leishmaniasis: a review. Med. Microbiol. Immunol. 190:93-95.
3. Contreras, V. T., J. M. Salles, N. Thomas, C. M. Morel, and S. Goldenberg. 1985. In vitro differentiation of Trypanosoma cruzi under chemically defined conditions. Mol. Biochem. Parasitol. 16:315-327.
4. Croft, S. L., R. A. Neal, W. Pendergast, and J. H. Chan. 1987. The activity of alkyl phosphorytcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36:2633-2636.
5. Croft, S. L., D. Snowdon, and V. Yardley. 1996. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. 38:1041-1047.
6. Escobar, P., V. Yardley, and S. L. Croft. 2001. Activities of hexadecylphosphocholine (miltefosine), Ambisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45:1872-1875.
7. Escobar, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop. 81:151-157.
8. Eue, I., R. Zeisig, and D. Arndt. 1995. Alkylphosphocholine-induced production of nitric oxide and tumor necrosis factor alpha by U937 cells. J. Cancer Res. Clin. Oncol. 121:350-356.
9. Eue, I. 2001. Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: participation of activated macrophages in the antitumor mechanism. Int. J. Cancer 92:426-433.
10. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used in Chagas' disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
11. Fischer, C., A. Voss, and J. Engel. 2001. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis. Med. Microbiol. Immunol. 190:85-87.
12. Freire-de-Lima, C. G., D. O. Nascimento, M. B. P. Soares, P. T. Bozza, H. C. Castro-Faria-Neto, F. G. de Mello, G. A. DosReis, and M. F. Lopes. 2000. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403:199-203.
13. Gantt, K. R., T. L. Goldman, M. L. McCormick, M. A. Miller, S. M. B. Jeronimo, E. T. Nascimento, B. E. Britigan, and M. E. Wilson. 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J. Immunol. 167:893-901.
14. 15N]nitrate in biological fluids. Anal. Biochem. 126:131-138.
15. Hilgard, P., T. Klenner, J. Stekar, and C. Unger. 1993. Alkylphosphocholines: a new class of membrane active anticancer agents. Cancer Chemother. Pharmacol. 32:90-95.
16. Hochhuth, C. H., K. Vehmeyer, H. Eibl, and C. Unger. 1992. Hexadecylphosphocholine induces INF-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell. Immunol. 141:161-168.
17. Jha, T. K., S. Sundar, C. P. Thakur, P. Bachmann, J. Karbwang, C. Fischer, A. Voss, and J. Berman. 1999. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniais. N. Engl. J. Med. 341:1795-1800.
18. Konstantinov, S. M., R. Kaminsky, R. Brun, M. R. Berger, and U. Zillmann. 1997. Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies. Acta Trop. 64:145-154.
19. Kuhlencord, A., T. Maniera, H. Eibl, and C. Unger. 1992. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36:1630-1634.
20. Leonard, R., J. Hardy, G. van Tienhoven, S. Houston, P. Simmonds, M. David, and J. Mansi. 2001. Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J. Clin. Oncol. 19:4150-4159.
21. Lira, R., L. M. Contreras, R. Santa-Rita, and J. A. Urbina. 2001. Mechanism of action of anti-proliferative lyso-phospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity, by sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. 47:537-546.
22. Lux, H., D. T. Hart, P. J. Parker, and T. Klenner. 1996. Ether-lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmania alkyl-phospholipid analogues. Adv. Exp. Med. Biol. 406:201-211.
23. Lux, H., N. Heise, T. Klenner, D. T. Hart, and F. R. Opperdoes. 2000. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111:1-14.
24. Martínez-Díaz, R. A., J. A. Escario, J. J. Nogal-Ruiz, and A. Gómez-Barrio. 2001. Biological characterization of Trypanosoma cruzi strains. Mem. Inst. Oswaldo Cruz 96:53-59.
25. Meirelles, M. N. L., T. C. Araújo-Jorge, C. F. Miranda, and H. S. Barbosa. 1986. Interaction of Trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro. Eur. J. Cell Biol. 41:198-205.
26. Michailowsky, V., S. M. F. Murta, L. Carvalho-Oliveira, M. E. S. Pereira, L. R. P. Ferreira, Z. Brener, A. J. Romanha, and R. T. Gazzinelli. 1998. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemothen 42:2549-2556.
27. Moncayo, A. 1999. Progress towards interruption of transmission of Chagas disease. Mem. Inst. Oswaldo Cruz 94:401-404.
28. Murray, H. W. 2000. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44:3235-3236.
29. Murray, H. W., and S. Delph-Etiene. 2000. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181:795-799.
30. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
31. Murray, H. W. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185-2197.
32. Murta, S. M., R. T. Gazzinelli, Z. Brener, and A. J. Romanha. 1998. Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol. Biochem. Parasitol. 93:203-214.
33. Neal, R. A., and J. van Bueren. 1988. Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro. Trans. R. Soc. Trop. Med. Hyg. 82:709-714.
34. Previato, J. O., C. Jones, L. P. B. Gon~alves, R. Wait, L. R. Travassos, and L. Mendonça-Previato. 1994. O-Glycosidically linked N-acetylglucosamine-bound oligosaccharides from glycoproteins of Trypanosoma cruzi. Biochem. J. 301:151-159.
35. Rybczynska, M., M. Spitaler, N. G. Knebel, G. Boeck, H. Grunicke, and J. Hofmann. 2001. Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities. Biochem. Pharmacol. 62:765-772.
36. Santa-Rita, R. M., H. S. Barbosa, M. N. S. L. Meirelles, and S. L. de Castro. 2000. Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop. 75:219-228.
37. Schmidt, H. H. W., P. Wilke, B. Evers, and E. Bohme. 1989. Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem. Biophys. Res. Commun. 165:284-291.
38. Seifert, K., M. Duchene, W. H. Wernsdorfer, H. Kollaritsch, O. Scheiner, G. Wiedermann, T. Hottkowitz, and H. Eibl. 2001. Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica. Antimicrob. Agents Chemother. 45:1505-1510.
39. Silva, J. S., G. N. R. Vespa, M. A. G. Cardoso, J. C. S. Aliberti, J. C. S., and F. Q. Cunha. 1995. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect. Immun. 63:4862-4867.
40. Sundar, S., F. Rosenkaimer, M. K. Makharia, A. K. Goyal, A. K. Mandal, A. Voss, P. Hilgard, and H. W. Murray. 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352:1821-1823.
41. Sundar, S., A. Makharia, D. K. More, G. Agrawal, A. Voss, C. Fischer, P. Bachmann, and H. W. Murray. 2000. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31:1110-1113.
42. Urbina, J. A. 1999. Parasitological cure of Chagas' disease: is it possible? Is it relevant? Mem. Inst. Oswaldo Cruz 94:349-355.
43. Walochnik, J., M. Duchene, K. Seifert, A. Obwaller, T. Hottkowitz, G. Wiedermann, H. Eibl, and H. Aspock. 2002. Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp. Antimicrob. Agents Chemother. 46:695-701.
44. Zeisig, R., M. Rudolf, I. Eue, and D. Arndt. 1995. Influence of hexadecylphosphorylcholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 121:69-75.